Last updated: 2026-09-16 12:10:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Lantheus Holdings, Inc. (LNTH) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $100.53, with a market capitalisation of $6.55B and a P/E ratio of 23.89. Over the past 52 weeks, its price has ranged from $49.67 to $111.86. This page covers its latest market performance, valuation, price trends and company information.
$6.55B | |
$100.74 | |
$126.89 | |
$1.76 | |
$100.73 | |
2.29K | |
1.36M | |
23.89 | |
$111.86 | |
$49.67 | |
-- | |
-- |
Lantheus Holdings, Inc. (LNTH) is trading at $100.53 in pre-market trading as of 2026-09-16 12:01:00, down 0.20% ($0.20) from the previous close of $100.73
Pre-market trading shows how investors are pricing LNTH before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Lantheus Holdings, Inc. (LNTH) moved from $100.97 to $100.53, representing a decline of 0.44% ($0.44).
The stock traded between $100.12 and $101.02 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.02 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81.8%
LNTH is currently trading at $100.53, placing it 81.8% of the way from its 52-week low of $49.67 to its 52-week high of $111.86. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 1193 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Lantheus Holdings, Inc. (LNTH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.